Galunisertib Exerts Antifibrotic Effects on TGF-β-Induced Fibroproliferative Dermal Fibroblasts

Keyphrases

• Fibroproliferative 100%
• Antifibrotic 100%
• Dermal Fibroblasts 100%
• Galunisertib 100%
• Wound Closure 33%
• Activin 33%
• Profibrotic Genes 33%
• Adverse Effects 16%
• Wound Healing 16%
• Protein Synthesis 16%
• Gene Expression 16%
• Attenuation 16%
• In Vitro Model 16%
• Fibroblast Proliferation 16%
• Fibronectin 16%
• Collagen 16%
• Fibrosis 16%
• Cell Proliferation 16%
• Cytotoxicity 16%
• α-smooth muscle Actin (α-SMA) 16%
• Phase II Clinical Trial 16%
• Small Molecule Inhibitors 16%
• Gene Expression Analysis 16%
• Proliferation Assay 16%
• Drug Action 16%
• Connective Tissue Growth Factor 16%
• Cancer Therapy 16%
• Cellular Migration 16%
• TGF Signaling 16%
• Scratch Test 16%
• Human Dermal Fibroblasts 16%
• Matrix metalloproteinase-1 (MMP-1) 16%
• Decorin 16%
• Cutaneous Scar 16%
• Pathological Scar 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Galunisertib 100%
• Wound 33%
• Phosphotransferase 33%
• Activin 33%
• Clinical Trial 16%
• Malignant Neoplasm 16%
• Adverse Event 16%
• Injury 16%
• Wound Healing 16%
• Fibronectin 16%
• Fibrosis 16%
• Connective Tissue Growth Factor 16%
• Alpha Smooth Muscle Actin 16%
• Interstitial Collagenase 16%
• Decorin 16%
• Cytotoxicity 16%